Andere Sprachen Almirall, S.A.

Aktien

A0MU8Y

ES0157097017

ALM

Realtime-Estimate Tradegate Andere Börsenplätze 14:55:57 26.04.2024			% 5 Tage	% 1. Jan.
8,53 ^EUR	+0,77 %		+3,58 %	+1,31 %

13.03.	Almirall unterzeichnet Lizenzvertrag mit Eloxx Pharmaceuticals zur Behandlung von Hautkrankheiten	MT
19.02.	Transcript : Almirall, S.A., 2023 Earnings Call, Feb 19, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

LE OPINIONI DEGLI ANALISTI DEL GIORNO : Moncler, Boreo, Fugro, STMicroelectronics, Alfen, Iberdrola, Roche, Temenos, Akzo Nobel...	25.04.
IN DIRETTA DAI MERCATI: Moncler, ENI, Webuild, Iberdrola, Adyen, SAES Getters, Xiaomi, Iberdrola, STMicro, Meta...	25.04.
EN DIRECTO DESDE LOS MERCADOS: Repsol, Almirall, Enagás, Iberdrola, Técnicas Reunidas, Aedas, Iberdrola, STMicro, Meta...	25.04.
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases	13.03.
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	13.03.
EN DIRECTO DESDE LOS MERCADOS: Grifols, Almirall, Santander, Enagás, Iberdrola, Air Liquide, Microsoft, Bayer, Capital One ...	20.02.
Cinco valores que se deben tener muy en cuenta por técnico este martes	20.02.
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	19.02.
Almirall : le titre bondit après un accord avec Novo Nordisk	19.02.
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	19.02.
Les prix américains plombent un peu l'ambiance	19.02.
En Direct des Marchés : Alstom, Forvia, Veolia, Casino, Apple, Nintendo, Super Micro Computer...	19.02.
EN DIRECTO DESDE LOS MERCADOS: Almirall, Santander, CaixaBank, Iberdrola, Apple, Repsol, Nintendo, Super Micro Computer...	19.02.
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology	19.02.
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	19.02.
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business	19.02.
Almirall, S.A. Provides Earnings Guidance for the Year 2024	19.02.
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	19.02.
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	21.12.
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	21.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Almirall, S.A.

Aktien

A0MU8Y

ES0157097017

ALM

Andere Sprachen

Filter